Evroxim powder for injections 750 mg. №10 vial


Manufacturer: Italy

Treatment of infections caused by microorganisms sensitive to cefuroxime, or treatment of infections before determining the pathogen of the infectious disease. Infectious diseases of the respiratory tract: acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative chest infections; infectious diseases of the throat and nose: sinusitis, tonsillitis, pharyngitis; infectious diseases of the urinary tract: acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria; infectious diseases of soft tissues: cellulite, erysipeloid, wound infection; infectious diseases of bones and joints: osteomyelitis, septic arthritis; infections in obstetrics and gynecology: infectious and inflammatory diseases of the pelvic organs; gonorrhea, especially in cases where penicillin is contraindicated; other infectious diseases, including septicaemia and meningitis.



Evroxim powder 750 mg Storage
active substance: 1 vial contains cefuroxime sodium (equivalent to cefuroxime)

750 mg or 1.5 g

Evroxim powder 750 mg Dosage form
Powder for injection.

Basic physical and chemical properties: white or almost white crystalline powder.

Pharmacotherapeutic group
Antibacterial agents for systemic use. Cephalosporins of the second generation. ATX code J01D C02.

Pharmacological properties


Evroxim powder 750 mg Mechanism of action

Cefuroxime inhibits the synthesis of the cell membrane of microorganisms by attaching to penicillin-binding proteins (PBP). This stops the biosynthesis of the cell wall (peptidoglycan), which leads to lysis and death of bacterial cells.

Mechanism of resistance

Bacterial resistance to cefuroxime may be associated with one or more of the following mechanisms:

hydrolysis by beta-lactamases, including (but not limited to) extended-spectrum beta-lactamases (BLRS) and AmpC enzymes that can be induced or stably activated in certain aerobic gram-negative bacterial species;
reducing the affinity of PZB for cefuroxime;
external membrane impermeability, which limits the access of cefuroxime to PZB in gram-negative bacteria;
bacterial efflux pumping systems.
Organisms that have acquired resistance to other injectable forms of cephalosporins are expected to be resistant to cefuroxime. Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may show decreased sensitivity or resistance to cefuroxime.

Infants and children> 3 weeks of age and children weighing <40 kg
Babies (from birth to 3 weeks)
Nosocomial pneumonia
from 30 to 100 mg / kg / day (intravenously) divided into 3 or 4 doses; for most infections, the optimal dose is 60 mg / kg / day

from 30 to 100 mg / kg / day (intravenously) divided into 2 or 3 doses

Complicated urinary tract infections, including pyelonephritis
Soft tissue infections: cellulite, erysipeloid, wound infections
Abdominal infections
Renal dysfunction

Cefuroxime is mostly excreted by the kidneys. Therefore, as with other similar antibiotics, it is recommended that patients with severe renal impairment reduce the dose of Euroxim to compensate for the slower excretion of the drug.

Hypersensitivity to cefuroxime or to other components of the drug.

Hypersensitivity to cephalosporin antibiotics.

Presence of a history of severe hypersensitivity (eg, anaphylactic reactions) to other beta-lactam antibiotics (penicillins, monobactams, and carbapenems).